Direct medical costs of liquid intravenous immunoglobulins in children, adolescents, and adults in Spain

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 566-575

  Darbà, Josep ^a   Restovic, Gabriela ^b   Kaskens, Lisette ^b   De Agustín, Tuy ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b BCN Health Economics and Outcomes Research SL   (Spain)

^c CSL Behring   (Spain)

Author keywords

allogeneic bone marrow transplantation; cost of illness; costs; immunomodulation; Intravenous immunoglobulin; replacement therapy

Indexed keywords

ACETYLSALICYLIC ACID; DEXCHLORPHENIRAMINE; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; OCTAGAMOCTA; PARACETAMOL; PREDNISONE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHILD; COST OF ILLNESS; DRUG COST; DRUG INDICATION; GUILLAIN BARRE SYNDROME; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOMODULATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREMEDICATION; PREVALENCE; SPAIN; SUBSTITUTION THERAPY;

ADOLESCENT; ADULT; AGE FACTORS; BONE MARROW TRANSPLANTATION; CHILD; COST OF ILLNESS; DRUG COSTS; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; QUESTIONNAIRES; SPAIN; TRANSPLANTATION, HOMOLOGOUS;

EID: 84859014294     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011399575     Document Type: Article

References (27)

1. Perayre M, Pastó L, Jódar R. Changes in the pattern of intravenous immunoglobulin use over a 5-year period. eur J Hosp Pharm Sci. 2006;12:67-71.
2. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin exp Immunol. 2005;142:1-11.
3. Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol. 2002;109:1001-1004. (Pubitemid 34634312)
4. Quartier P, Debre M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J Paediatr. 1999;134:589.
5. Bjorkander J, Nikoskelainen J, Leibl H, et al. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang. 2006;90:286-293.
6. Church JA, Leibl H, Stein MR, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IVIG 10%] in patients with primary immunodeficiency [published online ahead of print May 17, 2006]. J Clin Immunol. 2006;26:388-395. (Pubitemid 44051386)
7. Pendergrast JM, Sher GD, Callum JL. Changes inintravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995-2000. Vox Sang. 2005;89:150-160. (Pubitemid 41337053)
8. Fergusson D, Hutton B, Sharma M, et al. Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review. Transfusion. 2005;45:1640-1657.
9. Ruiz-Antorán B, Agustí Escasany A, Vallano Ferraz A, et al. Use of non-specific intravenous human immunoglobulins in Spanish hospitals: need for a hospital protocol [published online ahead of print March 5, 2010]. eur J Clin Pharmacol. 2010;66:633-641.
10. Högy B, Keinecke H, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment with antibody deficiencies for the perspective of the German statutory health insurance. eur J Health econ. 2005;50:24-29. (Pubitemid 40543267)
11. Kallenberg CGM, Laseur M. Cost considerations in choosing an intravenous immunoglobulin preparation. eur Hosp Pharm Pract. 2007;13:6-7.
12. Lozano Almela ML. Uso terapéutico de los derivados plasmáticos. Haematologica/edición española. 2005;90(suppl 1):46-53.
13. Farrugia A, Poulis P. Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfusion Med. 2001;11:63-74. (Pubitemid 32455656)
14. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: anupdate for clinicians. Transfusion. 2003;43:1460-1480. (Pubitemid 37322509)
15. Ratko T. Technology Assessment: Intravenous Immunoglobulin Preparations. Oak Brook, Ill: University HealthSystem Consortium; 1999.
16. Membe SK, Ho C, Cimon K, Morrison A, Kanini A, Roifman CM. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol Allergy Clin north Am. 2008;28:861-874.
17. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102:177-193. (Pubitemid 38887692)
18. Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy. 2005;25:78s-84s. (Pubitemid 41566908)
19. Chapel HM. Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissible agents. IUIS Committee on Primary Immunodeficiency Disease. International Union of Immunological Societies. Clin exp Immunol. 1999;118(suppl 1):29-34.
20. Pi D, Petraszco T. IVIG supply and cost. In: IVIG. utilization Management Handbook. 1st ed. Vancouver, BC: British Columbia Provincial Blood Coordinating Office; 2002.
21. Simoens S. Pharmacoeconomics of immunoglobulins in primary immunodeficiency. expert Rev Pharmacoecon Outcomes Res. 2009;9:375-386.
22. Rice DP. Cost of illness studies: what is good about them? Inj Prev. 2000;6:177-179.
23. Registro español de inmunodeficiencias primarias (REDIP). http://web.hsd.es/redip/index.php?l=es&m=inicio. Accessed August 9, 2010.
24. Instituto Nacional de Estadísticas (INE). http://www.ine.es/ jaxiBD/tabla.do?per=01&type=db&divi=EPOB&idtab=3. Accessed August 9, 2010.
25. Vademecum. http://www.vademecum.es. Accessed September 8, 2010.
26. CGCOF: Medicine database. Consejo General de Colegios Oficiales de Farmacéuticos. www.portalfarma.com. Accessed August 9, 2010.
27. Comas F, Matamoros N, Puigventós F, et al. Inmunoglobulinas intravenosas: estudio de utilización y redacción de un protocolo. Boletín Informativo de la Comisión de Farmacia y Terapéutica 1998; no. 20. http://www.sefh.es/privado/boletines/20.htm. Accessed August 9, 2009.